3.74
-0.1116(-2.90%)
Currency In USD
| Previous Close | 3.85 |
| Open | 3.82 |
| Day High | 3.82 |
| Day Low | 3.68 |
| 52-Week High | 7.6 |
| 52-Week Low | 3.36 |
| Volume | 330 |
| Average Volume | 2,845.7 |
| Market Cap | 139.66M |
| PE | -1.66 |
| EPS | -2.25 |
| Moving Average 50 Days | 3.7 |
| Moving Average 200 Days | 4.22 |
| Change | -0.11 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $190.09 as of September 29, 2025 at a share price of $3.735. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $601.48 as of September 29, 2025 at a share price of $3.735.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
GlobeNewswire Inc.
Aug 25, 2025 8:00 PM GMT
MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025IND filing on first radio-DARPin p
Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics
GlobeNewswire Inc.
Aug 21, 2025 5:00 AM GMT
Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursua
Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025
GlobeNewswire Inc.
Jun 22, 2025 8:00 PM GMT
MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor accumulation and attractive biodistribution shown in